Company intelligence / Profile preview

Orexa

Herpen, Netherlands

Ownership: Private
Development stage: Preclinical

Overview

Orexa has completed preclinical research and a successful Phase 1 trial showing strong signals. The current focus is on testing efficacy in patients during multiple ongoing or planned Phase 2 trials targeting increased food intake to improve health outcomes and reduce hospital stays. The lead compound is an oral proprietary formulation designed to increase food intake, based on a well-known anesthetic agent. The first patient was dosed in January/February of 2024 for the postoperative ileus trial.

Therapeutic areas: GastroenterologyPsychiatryMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

lidocaine hydrochloride monohydrate

Unknown

Beyond the preview

Go deeper on Orexa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orexa.

Explore the full profile